Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unfortunately for us (unless something like BRAVE changes things), there isn’t that much interest in Amarin at this time:
https://www.barrons.com/articles/biotech-abbvie-roche-stock-acquisitions-aa44cb59?mod=RSSMSNBarrons
I hold that stock and was looking at it this morning at $75 and thought since approval was expected I should dump and just then doorbell rings and window shutter installer here to do work. By the next chance I had it was below 70. Well at least there are no Generics that are in court with them so maybe in a few weeks it will continue upward.
Actually North the shares jumped up 6 bucks before FDA announcement but are now DOWN $7 after approval.
Reminiscing about seeing Led Zeppelin at the MTL Forum over 51 years ago, and simultaneously thinking of my Amarin investment I recall Led Zeppelin once sang, "And a new day will dawn, for those who stay Long, and the forest will echo in laugher"!
Hope this comes true for us.
Wonder if they will need to cut the divvy soon?
Thanks for the heads up. Looking quickly I don’t see a “basic” listed for Aetna. Also all the Aetna plans seem to have relatively good sized deductibles. Maybe I am missing something
You are lucky if it has only happened to you once. I know years back there were other posters who were in the stock longer than us, but I wonder if in the current crop of posters we are the longest owning (suffering)? My memory is fuzzy at my old age (and don’t to look it up) so I can’t give you a year my investment started here but it was before Marine.
Absolutely. Some here have said that won't or shouldn't happen, but it is a concern. Got to get the price up asap. Of course just getting over a buck doesn't necessarily mean there still couldn't be a reverse split. For companies losing money a RS just magnifies loss per share. Now if they were making profits a RS would increase profit per share but I have rarely seen RS helping. They just drive the sp down to what it was and you lose everything all over again.
And you can extend that "general public" comment to a good percentage of physicians. Not as high as the general public but appreciable nonetheless.
No question that is possible and most likely probably. However, I hope they are not getting the advice from the same group of lawyers that got them into this mess in the first place.
As much as you have harped on this over the years, you are more right than ever. At this point, only a BP can truly take V to the heights that it should. Of course, Denner will have to make some headway first in order to be able to convince BP that taking a flyer on V and spending resources on it makes profitable sense.
I know that over the most recent period, many of us here have been focusing on the upcoming BRAVE data to give Amarin, Vascepa, and the stock price a boost. I have been a little more sanguine about that trial's impact for us. I hope I am wrong and that it blows the top off. I have over the years thought that the CVD indication should have been plenty for all of us to make a windfall. Of course, management missteps and a really crummy justice system have put the kibosh on that up until now. But I noticed in the release that Lizzy posted last night, there is no mention of BRAVE or AD. Rather:
"We continue to believe in both the tremendous value of Vascepa/Vazkepa to cardiovascular patients worldwide and the market opportunity."
I am just hoping they can figure out a way to monetize this CVD indication for V.
If I wanted to be flippant I would say for sure because as my age progresses either Amarin solves its problems or I will croak.
More seriously, I turn 73 in 2025 and will have to start taking RMDs in that year so I sure hope I can monetize this investment by then so I can have some money to withdraw.
Being as you - a horrendously long holder of this stock - I thank you for posting this
Thanks for posting Lizzy. Good to know that someone running the company is as pissed as we are, but even better is that they are putting more of their money where their mouth is. Something we did not see in the past.
I guess the side effects were enough to get Pfizer to put a halt on their version of a similar drug. Of course I have read articles saying that semaglutide is flying off yhe shelves and drug stores are having a hard time staying stocked.
No I think you are correct. They are hurting themselves more. The only way this hurts Amarin in any way is if these Generics war with themselves and price it so low that insurance companies either swing with them or demand more concessions from Amarin.
Yep, it is a puzzlement. We all felt like it was terribly dumb of some of the first Generics to jump in rather than letting Amarin develop the market. So one or two with some stupid thinking could be, but can all these companies be so dumb? Maybe they are happy just collecting a few nickels. Of course since most if not all of these guys have many, many drugs they distribute it probably does not cost that much to throw another one into their offerings.
I know I shouldn't (water under the bridge) but every time there is some news concerning Generics selling V, I think of the disastrous decisions made by management concerning the trial. Venue selection, and not reaching some settlement rather than risking the whole business.
Wishing your wife the best. Take care
Wish the article had a little more data. On the surface this helps GL as much as any other drug.
Now it could be that V’s efficacy in R-I was so great that raised up the average when all the other omega-3 studies were added. Or, part of the reason that meta-analysis is questionable, is that the authors selectively chose those studies that favored this particular outcome. Heck the EU does not reimburse for any mixed omega-3 drugs for CVD.
Agreed
The main hope would be that it would help with EU sales. Not much hope for the US.
Noticed the volume spike at the end of the day there
We used to have a couple of posters pushing $100 after R-I but they no longer post here.
I wanted to report something positive that I came across yesterday. It is a single, solitary incident that unless it happens on a grand scale will not accomplish anything (especially with the insurance companies infringing) but it at least put a smile on my face for a few minutes.
As some may have caught in one of my posts, I have just recently moved clear across the country (a mistake for sure but I won't elaborate unless someone has to know) and yesterday I had my first appointment with a primary care physician. I did not know him, or even know much about him, and chose him because everyone else I called couldn't get me in until March or later and this guy is close to my new home.
He said he was 61 although he looked a lot younger. He seemed really sharp and knew his stuff. As we proceeded he started to run down the list of my meds (main reason to get a doc was to get my scripts refilled). He saw that I am on a tiny dose of atorvastatin and chimed in that he is on a statin as well and began to extoll the virtues and benefits of a statin. I started getting a little nervous at that point but then he came to Vascepa and I was shocked. He immediately praised the shit of out V and started reciting the results of the Reduce-It study. I quickly added that those RRR numbers he was spewing were on TOP of statin treatment.
So for a little while I was not as down on our medical establishment. Of course 1 does not a building make. More like a needle in a haystack. Unfortunately, he can write the script for V, but insurance companies and pharmacies will sub with generic. Speaking of all that, it has been almost a year since the HealthNet settlement, and I know it is under seal, but can anyone see any evidence of some benefit?
Don't want to disagree with your characterization of the state of affairs currently and the last couple of years, but, I would like to add a few things.
First, there is no question that if there was any interest in V from a BP that would have been around the time of R-I readout. Now, it is hard to imagine that anyone would be chomping at the bit to buy Amarin. So although we can be fairly confident that Denner would like to offload Amarin to a BP, it ain't that easy at this point.
Secondly, even if it appears that the situation is similar previous management, I would say that I prefer being in bed with someone who has put his own money into this investment. Prior management were just given shares. Anyway, let's all hope that something transpires so that we can at least get out of this investment with part of the shirt on our backs.
Would love to know who is prescribing that GL
No not necessary Sleven. Thanks for clarifying things up for me.
Any guesses after how many AD drugs are approved that the FDA will no longer consider it an unmet need?
Thanks DMC. We are all hoping V provides some positive results in this study. However, despite running the risk of incurring the wrath of this board imho I cannot see how after reading the following excerpt from your link, that anyone could conclude that V could possibly achieve FDA approval based on this trial:
“The overarching goal of this trial is to assess whether icosapent ethyl beneficially affects intermediate physiological measures associated with onset of AD in order to evaluate whether larger, multi-site, longer-duration Alzheimer's prevention trials are warranted to assess more definitive clinical outcomes. Hypothesis: In middle-aged and older cognitively-healthy Veterans with parental history of AD and high APOE4 prevalence, 18 months of treatment with icosapent ethyl will beneficially modify preclinical AD biomarkers, including regional cerebral blood flow, CSF markers of AD pathology, and cognitive performance. Specific Aim 1: To investigate the effects of 18 months of icosapent ethyl 4 g daily vs. placebo on arterial spin-labeling MRI regional cerebral blood flow in a pre-defined statistically-identified region of interest affected early in preclinical AD; Specific Aim 2: To determine the impact of 18 months of icosapent ethyl vs. placebo on CSF biomarkers of preclinical AD pathology (CSF ß-amyloid- 42, total tau, and phosphorylated tau181); Specific Aim 3: To evaluate the effects of 18 months of icosapent ethyl vs. placebo on a composite measure designed to assess preclinical cognitive changes - the Alzheimer's Disease Cooperative Study (ADCS) Preclinical Alzheimer's Cognitive Composite (PACC). If icosapent ethyl beneficially modifies AD biomarkers in at-risk Veterans, the results from the proposed trial would be used to develop multi-site, longer-duration clinical trials using the VA Cooperative Studies Program to assess the efficacy of icosapent ethyl on not only AD biomarkers, but also on more clinically definitive outcomes, such as rate of cognitive decline and conversion to mild cognitive impairment (MCI). If future studies show that icosapent ethyl delays the onset of AD by even an average of 5 years, estimates suggest that this could reduce the prevalence of AD by about 50%.”
Yep, and I feel fortunate for once. Took small position yesterday but got out this morning after the sp looked like it was losing momentum. Maybe down the road HSCS will be worth looking at. If insurance doesn’t cover this it will be a tough go.
Thanks Kiwi
Kiwi. Where do you see this heading? CDiO I mean as it seems they are considerably ahead of HSCS.
Come on, you know the answer. The article you posted was about a drug that does not have generic competition.
Ram, that is absolutely correct. No matter what brand name you give a drug it still is known by its chemical/generic name. So it is always icosapent ethyl no matter what.
Agreed PD. I was only thinking of the current situation and didn’t realize you could have been referring to what might happen if something extremely positive comes from BRAVE.
Excellent insight Pharmacydude. The only catch for us is that there is very little demand for V, so those searches for V on insurers’ formularies will probably not spike the needle enough to trigger being noticed. Thank you Du.
Dar, people like Nissen raise my ire and that the same make ashamed and embarrassed for the field of science. When I was young I found many subjects in school too subjective if you pardon the pun. I latched onto math and science and was drawn to them because of the framework, rules, methods, etc that made them objective rather than subjective.
Knowledge and truth is their goal. There is obviously much room for disagreement and discussion in science but to have some standing evidence needs to be provided. Nissen provides none, and much worse, willfully disregards gold standard data in front of his nose.
Thanks for posting. Someone needs to grab Nissen by the scruff of the neck and force feed him this data.